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Introduction
Over the past two decades, type 2 diabetes has emerged 
as an important medical problem in sub-Saharan Africa. 
Estimates by the International Diabetes Federation suggest 
that the largest increase in the prevalence of diabetes is 
expected to occur in the developing world, including Africa. 
However, there is a paucity of prevalence data from South 
Africa and the rates published in the few studies available 
vary depending on the populations studied, as well as the 
method used in the diagnosis.
Before 2009, the only acceptable tests for the diagnosis 
of diabetes were based on blood glucose values: either 
a fasting blood glucose (FPG) of at least 7 mmol/l or a 
random blood glucose of at least 11.1 mmol/l in a patient 
with symptoms of diabetes, or a blood glucose of at least 
11.1 mmol/l two hours after an oral glucose tolerance test 
(OGTT). In 2009 an expert committee of the American 
Diabetes Association (ADA) recommended the use of 
HbA1c to diagnose diabetes.
1 In 2010 the ADA adopted the 
proposal as part of the diagnostic criteria of diabetes, using 
a cut-off of equal to or greater than 6.5%. They modified the 
criteria for impaired fasting glucose and impaired glucose 
tolerance to include individuals with an HbA1c ranging 
from 5.7 to 6.4%, and recommended that the diagnosis 
should be confirmed with a repeat HbA1c test, unless there 
are clinical symptoms and blood glucose levels equal to 
or greater than 11.1 mmol/l. Their recommendations also 
state that the HbA1c must be measured in an accredited 
laboratory and that the different methods for diagnosing 
diabetes should not be used together, because of the lack 
of agreement between them.2
In 2009 the World Health Organization (WHO) conducted a 
systematic review of the use of HbA1c to diagnose diabetes, 
and made similar recommendations. They recommend that 
the HbA1c be used for the diagnosis of diabetes using a cut-
off value of 6.5%, provided that stringent quality assurance 
tests are in place and assays are standardised to criteria 
aligned to international reference values, and that there 
are no conditions present which preclude the accurate 
measurement of HbA1c.
3 The WHO also recommended that 
long-term prospective studies are carried out in various 
ethnic groups to establish the precise glucose and HbA1c 
levels predictive of microvascular and macrovascular 
complications. The WHO recommendation states that in 
an asymptomatic individual diagnosis should be confirmed 
with an additional test. It also cautions against the use of 
point-of-care devices, except where no other technology 
is available, and provided that stringent quality assurance 
programmes are in place.
The aim of this paper is to analyse the advantages and 
disadvantages of using HbA1c to diagnose diabetes in a 
multiracial society such as South Africa
Evidence for the use of HbA1c
Glycated haemoglobin reflects the average endogenous 
exposure to glucose, including postprandial spikes, and 
has low intra-individual variability, particularly in individuals 
without diabetes. It is these characteristics that may 
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contribute to its apparent superiority over fasting glucose in 
risk stratification for cardiovascular disease.
The evidence for the use of HbA1c for diagnosing diabetes 
is based on the examination of three cross-sectional 
epidemiological studies that included an Egyptian population 
(n = 1018), a Pima Indian group (n = 960) and the United 
States National Health and Nutrition Survey (NHANES, 
n = 2821). Each of these studies assessed FPG, two-hour 
glucose and HbA1c, and also measured the prevalence of 
retinopathy as assessed by fundus photography or direct 
ophthalmoscopy. The HbA1c values at which retinopathy 
increased in prevalence were between 6 and 7% and were 
similar among the three groups.1 It is important to note that, 
in at least two of these studies, the populations studied were 
homogenous. A systematic review of nine studies performed 
in Asian or European populations compared HbA1c with 
FPG for the diagnosis of diabetes and used WHO criteria 
as the gold standard. They reported that HbA1c and FPG 
were equally effective tools for the diagnosis of diabetes. 
An HbA1c equal to or greater than 6.1% had a sensitivity of 
78 to 81% and a specificity of 79 to 84% for the diagnosis 
of type 2 diabetes. When they used an FPG value of 6.1 
mmol/l as cut-off point, the sensitivity ranged between 48 
and 64% and the specificity ranged from 94 to 98%.4 In a 
population-based study from Singapore, the investigators 
showed that increasing HbA1c was associated with all 
microvascular complications, and that the optimal cut-off 
point for detecting mild and moderate retinopathy was 
between 6.6% and 7% respectively, with the prevalence of 
retinopathy being less than 1% below these cut-off points.5 
The Atherosclerosis Risk in Communities (ARIC) study is a 
community-based prospective cohort of middle-aged adults 
from the USA. In this study, data from more than 14 000 
black and white adults demonstrated that increasing HbA1c 
levels were associated with increasing values of FPG, but 
were more strongly associated with risk of cardiovascular 
disease and death from any cause compared with FPG.6
Comparison of HbA1c with other methods 
of diagnosing diabetes
Oral glucose tolerance test
OGTT is recognised as the gold standard in the diagnosis 
of diabetes and is a sensitive marker of impaired glucose 
tolerance. However, it requires stringent conditions, such as 
the ingestion of at least 150 g of carbohydrate per day for at 
least three days prior to the test, overnight fasting of at least 
10 hours, and preventing the patient from walking around 
during the test.7 These conditions not only influence the test 
results, but often make the test impractical. The OGTT also 
shows much greater intra-individual variability (16.7%) than 
the FPG or HbA1c.
8 It is because of these limitations that the 
ADA recommended FPG as the preferred glucose-based 
diagnostic test for diabetes.9
Fasting plasma glucose
Small increases in blood glucose substantially increase 
the risk of diabetes, but glucose measurement is affected 
by several preanalytical and analytical variables that make 
it difficult to apply these epidemiological principles to 
individual patients. Patients are seen by their physicians at 
any time of day and in an uncertain state of fasting. Fasting 
glucose levels show significant diurnal variation, which 
could impact on the diagnosis of diabetes.10
To reduce glycolysis, glucose is collected in fluoride tubes, 
after which it should be placed on ice and the plasma 
should be separated from the cells promptly.11 In spite of 
these precautions, the rates of decrease in glucose in the 
first hour after collection in tubes with and without fluoride 
are virtually identical, and the decrease in glucose after two 
hours in a fluoride tube can exceed 0.5 mmol/l.12
Another problem with the use of FPG alone for the diagnosis 
of diabetes is that, in epidemiological surveys, it results in a 
lower disease prevalence compared to the use of the OGTT, 
and it does not pick up those individuals with impaired 
glucose tolerance. Motala et al investigated diabetes 
and other disorders of glycaemia in rural KwaZulu-Natal 
and showed that if FPG alone was used, the prevalence 
of diabetes would be 36% lower than when a full OGTT 
was performed. If an OGTT was not performed, none of 
those subjects with impaired glucose tolerance would be 
detected.13 Soma and Rheeder noted in a group of 120 
subjects admitted for elective coronary angiography that 
nine out of 14 subjects would not have been detected as 
being diabetic if only an FPG level had been measured, as 
opposed to a full OGTT.14
Plasma is the preferred sample type for glucose 
measurement in the laboratory and there is variability when 
sample types differ. Whole-blood glucose concentrations 
are lower than plasma concentrations because of the lower 
water content of red blood cells, while plasma glucose 
concentrations have been reported to be lower, higher or 
the same as those in serum.15-18
HbA1c, on the other hand, does not require an overnight fast 
and it does not require morning blood collection. HbA1c is 
also reported to be relatively stable and shows less intra-
individual variability than FPG or two-hour glucose levels. 
This was illustrated by Selvin et al, who looked at short-term 
inter-individual variability of FPG and two-hour glucose and 
HbA1c in 685 participants without diagnosed diabetes, and 
showed high variability of both FPG and two-hour glucose 
levels relative to HbA1c levels.
8
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The case against HbA1c 
Despite its greater clinical convenience, preanalytical and 
biological stability, and assay standardisation, HbA1c has 
several limitations that preclude its use for the diagnosis of 
diabetes in South Africa at this time.
Methods of measuring HbA1c
Laboratories use a wide variety of analytical techniques to 
separate and then quantify HbA1c, based on differences in 
either molecular structure or molecular charge.
HbA1c is less positively charged at neutral pH than 
pyridoxylated normal adult human haemoglobin (HbAo), 
and this is the basis for the high-performance liquid 
chromatography (HPLC) method. Spectrophotometric 
analysis of the various eluants provides the percentage 
of each haemoglobin species in the sample. This method 
is rapid and has very good precision. In South Africa it is 
utilised in some private laboratories, as well as in some of the 
large academic hospitals. The separation of total glycated 
haemoglobin or HbA1c based on molecular structure can 
be achieved either by immunoassay or by boronate affinity 
chromatography. Immunoassays in particular may be 
affected by haemoglobinopathies. Several South African 
laboratories use immunoassay-based methods to separate 
glycated haemoglobin from the nonglycated haemoglobin 
(Cummins R, Fedler C, Zemlin A, personal communication).
Owing to simplicity of use, small sample volume 
requirements and portability, there is interest in the use 
of point-of-care devices for the measurement of HbA1c. 
While these are acceptable for the monitoring of glycaemic 
control in diabetic patients, the ADA cautions that point-
of-care devices should not be used for the diagnosis of 
diabetes. An evaluation of eight NGSP (previously the 
National Glycohemoglobin Standardization Program) 
-certified HbA1c point-of-care instruments showed that only 
two of these instruments met the acceptance criteria of 
having a coefficient of variation (cv) of less than 3%, and all 
the instruments showed significant differences in analytical 
performance between different reagent lot numbers.19 In 
addition, point-of-care tests cost more than laboratory-
based methods (George J, personal observation). There is 
no objective information concerning their performance in 
the hands of those who use them, and proficiency testing 
might not be carried out.
Standardisation and quality assurance
The ADA endorsement of HbA1c for the diagnosis of 
diabetes is based partly on the fact that assays are now 
highly standardised.20 This process began in 1993, 
when the American Association for Clinical Chemistry 
(AACC) established a Glycohaemoglobin Standardization 
Subcommittee to formulate a strategy to harmonise 
glycated haemoglobin results. The goal of the NGSP was 
to standardise HbA1c results so that values reported by 
clinical laboratories were comparable to those reported by 
the Diabetes Control and Complications Trial (DCCT). The 
rationale for this was that the DCCT showed that risks for 
complications in patients with diabetes were directly related 
to glycaemic control as measured by HbA1c. In 2001, a 
reference method and reference material was developed by 
a working group of the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC), and this method 
is used by manufacturers to standardise assays.21 When 
the results of pooled blood samples in the IFCC and NGSP 
networks were compared they showed that the relationship 
is linear: NGSP % = (0.915 × IFCC %) + 2.15. While there 
is good linear correlation between the NGSP and IFCC 
results, the absolute HbA1c values differ by 1.5 to 2%. The 
IFCC wanted HbA1c reported as mmol/mol, but because of 
concerns about possible confusion arising if patients’ HbA1c 
values were changed, agreement was reached between 
the IFCC and major diabetes organisations to report IFCC 
HbA1c results (mmol/mol) as the equivalent NGSP DCCT-
aligned result (percentage based on the equation). 
All methods used by the major laboratories in South 
Africa are NGSP certified. This means that, for a panel of 
40 samples analysed in duplicate under ideal conditions, 
the 95% confidence interval of the difference between the 
method being tested and an NGSP reference laboratory 
would be within ± 0.75% HbA1c. Method certification is 
performed by the manufacturer. Laboratories can obtain 
documentation from the manufacturer on their system’s 
performance and traceability to DCCT, and should do so, 
but this does not guarantee accuracy and precision in the 
clinical laboratory. Laboratories should therefore participate 
in external proficiency testing programmes using whole- 
blood quality control material. There is no national quality 
assurance programme for HbA1c in South Africa at this 
time, nor are there data on methodologies currently in use, 
or on participation and performance in proficiency testing. 
Until laboratories here demonstrate that their assays 
are aligned to international reference values and proper 
quality assurance criteria are adhered to, and that these 
laboratories are accredited as stipulated by both the ADA 
and the WHO, HbA1c should not be used for the diagnosis 
of diabetes. 
Ethnicity
A number of studies have shown that the cut-off of 6.5%, 
as proposed by the ADA, is not optimal for the diagnosis 
of diabetes in some ethnic groups. In an Indian population 
a cut-off equal to or greater than 6.1% was shown to have 
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better diagnostic performance than a cut-off of 6.5%.22 It 
appears that people of African descent have higher levels 
of glycated haemoglobin across the full spectrum of 
glycaemia.23 Analysis of data from over 2 000 nondiabetic 
individuals in the NHANES III population showed that the 
HbA1c level increased with age and with ethnicity. In non-
Hispanic blacks, and using HbA1c levels of 6.5 to 6.9%, 
87% of those over the age of 64 years would not have 
diabetes by FPG/OGTT criteria.24 Jorgensen et al assessed 
whether ethnicity modified the association between glucose 
levels and HbA1c among Greenland Inuit, Inuit immigrants in 
Denmark and the general Danish population.25 They looked 
at OGTT and HbA1c. All three groups had an increase in 
prevalence when HbA1c was used for diagnosis. However, 
this was most dramatic for the Greenland Inuit, with  a jump 
from 11.2% (OGTT) to 31.7% (HbA1c). Another drawback 
of the use of HbA1c at this time is that studies comparing 
FPG- and HbA1c-based diagnosis often produce discordant 
results. Analyses of data from nondiabetic Koreans showed 
that 31.6% of the subjects would have been classified as 
having diabetes based on FPG, while only 23.5% would 
have been classified as having diabetes using HbA1c value 
of 6.5%.26 
What these studies tell us is that, in some population groups, 
using FPG to diagnose diabetes results in an increased 
prevalence when compared to the use of HbA1c, while the 
opposite is observed in other populations. The selection 
of a diagnostic threshold is usually made by means of the 
receiver operating characteristics curve (ROC) approach, 
followed by its validation in the target population using 
likelihood ratios. This evidence is lacking for South Africa. 
In addition to ethnicity, other factors that affect HbA1c levels 
include age, anaemia, human immunodeficiency virus 
(HIV) status, renal failure, erythrocyte biochemistry and 
haemoglobinopathies.
Ageing
Most data on the use of HbA1c for the diagnosis of diabetes 
are based on studies carried out in adults. A cross-sectional 
analysis of data from the NHANES III group demonstrated 
a consistent increase in HbA1c with age.
27 There are limited 
data from children. One recent study carried out on a 
multiethnic cohort of children and adolescents suggests 
that a cut-off value of 6.5% underestimates the prevalence 
of diabetes in children.28 Thirty per cent of the population in 
South Africa is under the age of 15 and 8% is over the age 
of 60, and the use of the prescribed cut-off of 6.5% may be 
inaccurate in both these groups.29 At present, neither the 
WHO nor the ADA advocates the use of age-appropriate 
reference ranges.
Renal failure
There are few data on the prevalence of chronic kidney 
disease in Africa, but the general impression is that it is 
three to four times more frequent than in more developed 
countries.30 Chronic kidney disease may falsely increase 
or decrease HbA1c levels. Increased values can arise from 
increased blood urea levels, which cause the formation 
of carbamylated haemoglobin and which then results in 
overestimation of haemoglobin using electrical charge-
based assays.31 These patients often have a shortened red 
blood cell life span and this would potentially reduce HbA1c 
levels.32
HIV infection
A report from the Women’s Interagency HIV study, which 
looked at FPG and HbA1c in HIV-infected and noninfected 
women, showed that HbA1c levels are slightly lower in 
HIV-infected women than in noninfected women; this was 
mainly due to higher mean corpuscular volumes.22 In the 
proceedings from the Conference on Retroviruses and 
Opportunistic Infections 2011, investigators showed that 
using an HbA1c cut-off of 6.5% would have diagnosed only 
nine out of 22 patients not previously known to be diabetic, 
and that in this small group of subjects the optimal cut-off 
for diagnosis was 5.8%. Of interest was that the use of 
antiretroviral drugs showed a variable influence on the test 
characteristics of HbA1c, with protease inhibitors leading 
to an underestimation of HbA1c levels and non-nucleoside 
reverse transcriptase inhibitors, particularly efavirenz, 
overestimating HbA1c levels.
33 This has major implications 
for our population, which has a high prevalence of HIV 
infection, and the use of efavirenz in first-line drug treatment. 
Glycation gap and erythrocyte biochemistry
One of the explanations put forward for the observed 
differences in sensitivity and specificity of HbA1c as a 
diagnostic tool is the differences in rates of glycation of 
haemoglobin.34 Yudkin et al introduced the terms “high 
glycators” and “low glycators” to describe individuals with 
higher or lower HbA1c levels relative to their glucose.
35 
Studies comparing intracellular glycation, as assessed 
by HbA1c, with extracellular glycation, as assessed by 
glycated serum proteins, have shown very strong within-
person correlation between HbA1c and fructosamine, but 
substantial between-person variation in the relationship 
between fructosamine and HbA1c.
36 This tells us that that 
there are large inter-individual differences between HbA1c 
and glucose. Biochemical differences in glucose transport 
across red cell membranes, subclinical variation in 
erythrocyte survival, and inherited differences in glycation 
rates all contribute to the glycation gap.37-39
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Anaemia, iron deficiency and haemoglobinopathies
Conditions that alter red cell life span alter HbA1c 
concentrations, with conditions that shorten red cell 
survival, such as haemolysis, decreasing HbA1c, and those 
disease states that prolong red cell survival increasing 
HbA1c.
37 Sickle-cell haemoglobin (HbS) has a valine for 
glutamic acid substitution at position 6 of the b chain. HbC 
is a variant mutation at the same site as the sickle cell 
mutation. Because the S and C variants are close to the N 
terminus of the b chain, some immunoassays are affected 
by the presence of these variants. These variants do affect 
the ionic charge of the haemoglobin molecule, and this 
may interfere with ion exchange methods. However, careful 
inspection of chromatograms should identify the presence 
of abnormal haemoglobin variants and alternate methods 
may be used.
No whole-blood method is suitable for the assessment of 
glycaemic control in patients homozygous for HbS, HbC or 
HbSC. The prevalence of sickle cell disease in indigenous 
South Africans is low, but can be very high in populations 
from the malaria-endemic regions of Africa.40
Iron deficiency has been shown to increase HbA1c by up 
to 2%.41 This is reversed by iron supplementation.42 The 
prevalence of iron deficiency in an urban South African 
female population despite iron fortification was estimated 
to be about 10%,43 while the prevalence in rural populations 
might be higher, at between 18% and 25%.44,45 In view of 
these patient variables it is likely that the use of HbA1c at a 
cut-off level of 6.5% will lead to overdiagnosis in the elderly, 
those with iron deficiency and some rapid glycators, while 
those with renal failure, haemoglobinopathies and slow 
glycators will be underdiagnosed. 
Given the high prevalence of HIV infection in our population, 
and the frequency with which subjects with diabetes have 
other medical illnesses, the likelihood that such factors 
may alter HbA1c is high. Thus it is imperative that large 
epidemiological studies be undertaken in such patient 
groups in South Africa to assess the diagnostic accuracy of 
HbA1c measurement.
Costs and availability
The cost of HbA1c is more than double that of plasma 
glucose, but is cheaper than the cost of the OGTT, which 
includes the cost of a glucose load and two glucose 
measurements. However, it is probable that other tests will 
be required in a significant proportion of cases and this 
will increase the economic burden on the health system. 
Currently there are no reliable data on the availability of the 
HbA1c test in South Africa. 
Conclusion
In conclusion, high HbA1c levels are clearly associated 
with incident microvascular complications in cohorts of 
previously diagnosed diabetics. The available evidence 
supports the role of HbA1c as a marker of glycaemic control 
and as a prognostic marker for future complications. 
However, there is insufficient evidence from South Africa 
at this time to recommend it as the method of choice for 
diagnosis. Before it can be recommended for the diagnosis 
of diabetes in South Africa, it is important to assess the 
methodologies currently in use and to ensure that they 
are reliable and traceable to the DCCT method. It is also 
important that laboratories are accredited and participate in 
external proficiency programmes. We should work towards 
the use of NGSP-certified methods for all diagnostic 
laboratories, and a national quality control programme for 
HbA1c measurement.
Appropriate cut-off levels for the population should be 
determined, based on the association between HbA1c, FPG, 
two-hour glucose levels and microvascular complications. 
Furthermore, the effects of common diseases, such as HIV 
and malaria, and the effects of antiretroviral therapy on 
the utility of HbA1c for the diagnosis of diabetes must be 
assessed.
Wild et al estimated that, in 2000, more than seven million 
people in sub-Saharan Africa had diabetes, with a projected 
increase to over 17 million by 2030. These projections do not 
take into account the effect of urbanisation and associated 
increases in rates of obesity across much of urban Africa.46 
Prospective evaluations should be carried out to assess 
the clinical and economic consequences of modification of 
the current diagnostic criteria. In the meantime, we should 
ensure that the majority of the population has access to 
plasma glucose and the OGTT for the diagnosis of diabetes.
Presently, the HbA1c should continue to be used as a means 
of monitoring diabetes control in South Africa, but not for 
its diagnosis.
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